## Goals of the Pandemic Response


#### Minimize serious illness and overall deaths


- Reduce the spread of infection through promotion of individual and community actions
- · Protect the population through provision of pandemic vaccine and implementation of other public health measures
- Provide treatment and support for large numbers of persons while maintaining other essential services


### Minimize societal disruption


- Support the continuity of health care and other essential services
- Support the continuation of day-to-day activities as much as possible and promote a return to normal community functioning as soon as possible
- Maintain trust and confidence through support of evidence-informed decision-making by collection, analysis and sharing of
  surveillance and other scientific information; and communicate appropriate and timely advice to decision-makers, health
  professionals and the public
- Support a coordinated response by working collaboratively with all levels of government and stakeholders


BC Centre for Disease Control
Provincial Health Services Authority



















# Lower income tied to worse economic & health consequences

Individuals with incomes less than \$60,000 had increased difficulty meeting financial need, were more food insecure and were more likely to be out of work.



% of respondents reporting economic impacts since pandemic



## In Canada

### Agreements announced with:

Company	Vaccine type	Clinical phase	# doses (Canada)	Reported efficacy
Medicago	Subunit	Phase 2	≤76m doses	
Novavax	Subunit	Phase 3	≤76m doses	
Sanofi/GlaxoSmithKline	Subunit	Phase 2	≤72m doses	
Moderna (S-2P)	RNA	Phase 3	≤56m doses	95% (interim)*
Pfizer/BioNTech (RBD)	RNA	Phase 3	≥20m doses	95%**
Johnson & Johnson	Viral vector	Phase 3	≤38m doses	
Oxford University/Astra Zeneca	Viral vector	Phase 3	≤20m doses	

<sup>\*162/170</sup> cases in placebo group; 0 severe cases in vaccine group; 11 severe cases in placebo group \*\*90/95 cases in placebo group; 1 severe case in vaccine group; 9 severe cases in placebo group

